KRdc as induction therapy shows improved OS for NDMM patients

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

The use of IORT at L'Hospitalet de Llobregat

Understanding intraoperative radiation therapy for early stage breast cancer

The use of IORT at Montefiore Medical Center

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer

Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM